Radioactive antibodies: a historical review of selective targeting and treatment of cancer.
Radioactive antibodies have served as imaging and therapeutic agents for several decades, but recent developments raise enthusiasm that a new generation of cancer therapeutics and diverse molecular imaging agents for various cancers are more likely than ever before. This article traces the development of tumor-targeting antibodies labeled with diagnostic or therapeutic radionuclides, and describes the problems encountered and the clinical advances made. We also emphasize recent attempts to improve both molecular imaging and radioimmunotherapy with multistep pretargeting methods that separate the delivery of the tumor-binding, bispecific antibody given in the first step from the radionuclide carrier, which, in the second step, will localize to the "anti-carrier" binding arm of the pretargeted bispecific antibody.
Goldenberg
David M
DM
Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Bellville, NJ 07109, USA. dmg.gscancer@att.net
Sharkey
Robert M
RM
D018033:Antibodies, Bispecific / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008967:Molecular Biology; D057054:Molecular Imaging / Q000379:methods; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000737:chemistry
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D011868:Radioisotopes